Elderly Hip Replacement
Conditions
Interventions
Group A Remimazolam Tosilate 0.2mg/kg/h:Administering different doses of remimazolam tobramate for anesthetic maintenance (0.2mg/kg/h)
Group B Remimazolam Tosilate 0.4mg/kg/h:Administering different doses of remimazolam tobramate for anesthetic maintenance (0.4mg/kg/h)
Group C Remimazolam Tosilate 0.6mg/kg/h:Administering different doses of remimazolam tobramate for anesthetic maintenance (0.6mg/kg/h)
Sponsors
Affiliated Hospital of Guizhou Medical University
Eligibility
Sex/Gender
All
Age
60 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) Patients scheduled for elective hip replacement surgery in the elderly 2) Patients aged 60 to 80 years 3) Patients with American Society of Anesthesiologists (ASA) physical status classification II to III 4) Patients with a Body Mass Index (BMI) between 18.5 and 23.9 kg/m² 5) Patients who voluntarily sign an informed consent form
Exclusion criteria
Exclusion criteria: 1) Patients known to be allergic to anesthetic drugs used in this study 2) Patients with myasthenia gravis, schizophrenia, and severe depressive states 3) Patients with concurrent severe malignant tumors, hematological diseases, and impaired liver or kidney function 4) Patients with obvious circulatory and respiratory dysfunction 5) Patients expected to be admitted to the ICU after surgery 6) Patients with an MMSE score <18 7) Patients who have received benzodiazepine treatment or participated in other clinical studies within the past 3 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intraoperative hemodynamic change indicators (MAP, HR); | — |
Secondary
| Measure | Time frame |
|---|---|
| Occurrence of low blood pressure;Average arterial pressure and HR of patients at different time points; | — |
Countries
China
Contacts
Public ContactJinli Wu
Affiliated Hospital of Guizhou Medical University
Outcome results
None listed